Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,157.08
-27.5500-2.33%
Post-market: 1,162.345.26+0.45%19:24 EDT
Volume:3.41M
Turnover:4.00B
Market Cap:1.09T
PE:38.84
High:1,215.00
Open:1,186.49
Low:1,155.27
Close:1,184.63
52wk High:1,292.65
52wk Low:763.30
Shares:945.38M
Float Shares:939.00M
Volume Ratio:1.68
T/O Rate:0.36%
Dividend:6.69
Dividend Rate:0.58%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:32.29
PE(LYR):50.42

Loading ...

DexCom’s Oura Bet: Potential Investment Gains Meet a Bigger Healthcare Opportunity

Bellwether Stocks Movement
·
Sep 29

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
43 mins ago

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
1 hour ago

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
1 hour ago

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
1 hour ago

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
1 hour ago

Sector Update: Healthcare

MT Newswires Live
·
6 hours ago

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
6 hours ago

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Yesterday

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Yesterday

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Yesterday

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Yesterday

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Yesterday

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Yesterday

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Yesterday

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Yesterday

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Yesterday

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Yesterday